116 related articles for article (PubMed ID: 27529457)
21.
Srisuttayasathien M; Areepium N; Lertkhachonsuk R
Per Med; 2021 Mar; 18(2):107-114. PubMed ID: 33565324
[No Abstract] [Full Text] [Related]
22. Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia?
Mora PAR; Sun SY; Velarde GC; Filho JR; Uberti EH; Dos Santos Esteves APV; Elias KM; Horowitz NS; Braga A; Berkowitz RS
Gynecol Oncol; 2019 May; 153(2):277-285. PubMed ID: 30857648
[TBL] [Abstract][Full Text] [Related]
23. Predictive factors of relapse in low-risk gestational trophoblastic neoplasia patients successfully treated with methotrexate alone.
Couder F; Massardier J; You B; Abbas F; Hajri T; Lotz JP; Schott AM; Golfier F
Am J Obstet Gynecol; 2016 Jul; 215(1):80.e1-7. PubMed ID: 26829503
[TBL] [Abstract][Full Text] [Related]
24. [EMA/CO regimen for chemotherapy 24 patients with ultra high-risk gestational trophoblastic neoplasia].
Shen T; Chen LL; Qin JL; Wang XY; Cheng XD; Xie X; Lyu WG
Zhonghua Fu Chan Ke Za Zhi; 2018 Jun; 53(6):371-376. PubMed ID: 29961278
[No Abstract] [Full Text] [Related]
25. Treatment of low-risk gestational trophoblastic neoplasia.
Winter MC
Best Pract Res Clin Obstet Gynaecol; 2021 Jul; 74():67-80. PubMed ID: 33741258
[TBL] [Abstract][Full Text] [Related]
26. Gestational trophoblastic neoplasia: treatment outcomes from a single institutional experience.
Al-Husaini H; Soudy H; Darwish A; Ahmed M; Eltigani A; Edesa W; Elhassan T; Omar A; Elghamry W; Al-Hashem H; Al-Hayli S; Madkhali I; Ahmad S; Al-Badawi IA
Clin Transl Oncol; 2015 May; 17(5):409-15. PubMed ID: 25398721
[TBL] [Abstract][Full Text] [Related]
27. Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia.
Winter MC; Tidy JA; Hills A; Ireson J; Gillett S; Singh K; Hancock BW; Coleman RE
Gynecol Oncol; 2016 Dec; 143(3):565-570. PubMed ID: 27756557
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience.
Maestá I; Nitecki R; Horowitz NS; Goldstein DP; de Freitas Segalla Moreira M; Elias KM; Berkowitz RS
Gynecol Oncol; 2018 Jan; 148(1):161-167. PubMed ID: 29092742
[TBL] [Abstract][Full Text] [Related]
29. [Curative effects and influenced factors of primary chemotherapy with single-agent methotrexate on low-risk gestational trophoblastic neoplasia].
Wu XD; Chen LL; Shen T; Chen SS; Chen QQ; Qin JL; Fu YF; Lü WG
Zhonghua Yi Xue Za Zhi; 2017 Jun; 97(23):1769-1772. PubMed ID: 28647996
[No Abstract] [Full Text] [Related]
30. A 30-year experience in using oral methotrexate as initial treatment for gestational trophoblastic neoplasia regardless of risk group.
Faaborg L; Niemann I; Ostenfeld EB; Hansen ES; Sunde L; Lindegaard JC
Acta Oncol; 2016; 55(2):234-9. PubMed ID: 26106854
[TBL] [Abstract][Full Text] [Related]
31. Comparison of treatment for low-risk GTN with standard 8-day MTX/FA regimen versus modified MTX/FA regimen without chemotherapy on the weekend.
Braga A; de Souza Hartung Araújo C; Mora PAR; Paulino E; de Melo AC; Velarde GC; Dos Santos Esteves APV; Junior JA; Filho JR; Elias KM; Horowitz NS; Berkowitz RS
Gynecol Oncol; 2020 Mar; 156(3):598-605. PubMed ID: 31928806
[TBL] [Abstract][Full Text] [Related]
32. The added value of hysterectomy in the management of gestational trophoblastic neoplasia.
Eysbouts YK; Massuger LFAG; IntHout J; Lok CAR; Sweep FCGJ; Ottevanger PB
Gynecol Oncol; 2017 Jun; 145(3):536-542. PubMed ID: 28390821
[TBL] [Abstract][Full Text] [Related]
33. Low-risk gestational trophoblastic neoplasia outcome after treatment with VMP regimen from 2005 to 2017.
Zhu CC; Liu HY; Wei Y; Shen Z; Qian LL; Song WG; Wang J; Wu DB; Zhang XF; Zhou Y
Taiwan J Obstet Gynecol; 2019 May; 58(3):332-337. PubMed ID: 31122520
[TBL] [Abstract][Full Text] [Related]
34. Management and survival of patients with FIGO high-risk gestational trophoblastic neoplasia: the U.K. experience, 1995-2010.
Agarwal R; Alifrangis C; Everard J; Savage PM; Short D; Tidy J; Fisher RA; Sebire NJ; Harvey R; Hancock BW; Coleman RE; Seckl MJ
J Reprod Med; 2014; 59(1-2):7-12. PubMed ID: 24597279
[TBL] [Abstract][Full Text] [Related]
35. Resistance to single-agent chemotherapy and its risk factors in low-risk gestational trophoblastic neoplasms.
Mousavi AS; Zamani A; Khorasanizadeh F; Gilani MM; Zendehdel K
J Obstet Gynaecol Res; 2015 May; 41(5):776-83. PubMed ID: 25492546
[TBL] [Abstract][Full Text] [Related]
36. Pulse actinomycin D as first-line treatment of low-risk post-molar non-choriocarcinoma gestational trophoblastic neoplasia.
Li L; Wan X; Feng F; Ren T; Yang J; Zhao J; Jiang F; Xiang Y
BMC Cancer; 2018 May; 18(1):585. PubMed ID: 29792175
[TBL] [Abstract][Full Text] [Related]
37. First-line hysterectomy for women with low-risk non-metastatic gestational trophoblastic neoplasia no longer wishing to conceive.
Bolze PA; Mathe M; Hajri T; You B; Dabi Y; Schott AM; Patrier S; Massardier J; Golfier F
Gynecol Oncol; 2018 Aug; 150(2):282-287. PubMed ID: 29887485
[TBL] [Abstract][Full Text] [Related]
38. The WHO score predicts treatment outcome in low risk gestational trophoblastic neoplasia patients treated with weekly intramuscular methotrexate.
Gilani MM; Fariba B; Behtash N; Ghaemmaghami F; Moosavi AS; Rezayof E
J Cancer Res Ther; 2013; 9(1):38-43. PubMed ID: 23575072
[TBL] [Abstract][Full Text] [Related]
39. Low-Risk Gestational Trophoblastic Neoplasia in Manitoba: Experience With Alternating Methotrexate and Dactinomycin.
Carlson V; Walters L; Lambert P; Dean E; Lotocki R; Altman AD
Int J Gynecol Cancer; 2018 Oct; 28(8):1448-1452. PubMed ID: 30095710
[TBL] [Abstract][Full Text] [Related]
40. Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasia.
Even C; Pautier P; Duvillard P; Floquet A; Kerbrat P; Troalen F; Rey A; Balleyguier C; Tazi Y; Leary A; Augereau P; Morice P; Droz JP; Fizazi K; Lhommé C
Eur J Cancer; 2014 Aug; 50(12):2082-9. PubMed ID: 24910417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
